159 related articles for article (PubMed ID: 32978826)
1. Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH-producing adenomas.
Gil J; Marques-Pamies M; Jordà M; Fajardo-Montañana C; García-Martínez A; Sampedro M; Serra G; Salinas I; Blanco A; Valassi E; Sesmilo G; Carrato C; Cámara R; Lamas C; Casano-Sancho P; Alvarez CV; Bernabéu I; Webb SM; Picó A; Marazuela M; Puig-Domingo M;
Clin Endocrinol (Oxf); 2021 May; 94(5):811-819. PubMed ID: 32978826
[TBL] [Abstract][Full Text] [Related]
2. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience.
Brzana J; Yedinak CG; Gultekin SH; Delashaw JB; Fleseriu M
Pituitary; 2013 Dec; 16(4):490-8. PubMed ID: 23184260
[TBL] [Abstract][Full Text] [Related]
3. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.
Karavitaki N; Turner HE; Adams CB; Cudlip S; Byrne JV; Fazal-Sanderson V; Rowlers S; Trainer PJ; Wass JA
Clin Endocrinol (Oxf); 2008 Jun; 68(6):970-5. PubMed ID: 18031313
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies.
Gatto F; Arvigo M; Ferone D
J Endocrinol Invest; 2020 Nov; 43(11):1543-1553. PubMed ID: 32557353
[TBL] [Abstract][Full Text] [Related]
5. Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly.
Tomasik A; Stelmachowska-Banaś M; Maksymowicz M; Czajka-Oraniec I; Raczkiewicz D; Zieliński G; Kunicki J; Zgliczyński W
Front Endocrinol (Lausanne); 2022; 13():957301. PubMed ID: 36187106
[TBL] [Abstract][Full Text] [Related]
6. Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response.
Gil J; Marques-Pamies M; Valassi E; García-Martínez A; Serra G; Hostalot C; Fajardo-Montañana C; Carrato C; Bernabeu I; Marazuela M; Rodríguez-Lloveras H; Cámara R; Salinas I; Lamas C; Biagetti B; Simó-Servat A; Webb SM; Picó A; Jordà M; Puig-Domingo M
Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203668
[TBL] [Abstract][Full Text] [Related]
7. Normal Insulin-like Growth Factor 1 During Somatostatin Receptor Ligand Treatment Predicts Surgical Cure in Acromegaly.
Losa M; Garbin E; Pedone E; Mortini P
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32609842
[TBL] [Abstract][Full Text] [Related]
8. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.
Petrossians P; Borges-Martins L; Espinoza C; Daly A; Betea D; Valdes-Socin H; Stevenaert A; Chanson P; Beckers A
Eur J Endocrinol; 2005 Jan; 152(1):61-6. PubMed ID: 15762188
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas.
Cuevas-Ramos D; Fleseriu M
J Mol Endocrinol; 2014 Jun; 52(3):R223-40. PubMed ID: 24647046
[TBL] [Abstract][Full Text] [Related]
10. Epithelial-Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly.
Gil J; Jordà M; Soldevila B; Puig-Domingo M
Front Endocrinol (Lausanne); 2021; 12():646210. PubMed ID: 33790868
[TBL] [Abstract][Full Text] [Related]
11. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
[TBL] [Abstract][Full Text] [Related]
12. miR-383-5p, miR-181a-5p, and miR-181b-5p as Predictors of Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.
Henriques DG; Miranda RL; Dezonne RS; Wildemberg LE; Camacho AHDS; Chimelli L; Kasuki L; Lamback EB; Guterres A; Gadelha MR
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769196
[TBL] [Abstract][Full Text] [Related]
13. Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.
Coopmans EC; Korevaar TIM; van Meyel SWF; Daly AF; Chanson P; Brue T; Delemer B; Hána V; Colao A; Carvalho D; Jaffrain-Rea ML; Stalla GK; Fajardo-Montañana C; Beckers A; van der Lely AJ; Petrossians P; Neggers SJCMM
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32589751
[TBL] [Abstract][Full Text] [Related]
14. The effect of somatostatin analogues on Ki-67 levels in GH-secreting adenomas.
Selek A; Cetinarslan B; Canturk Z; Tarkun I; Hanazay Y; Vural C; Anik I; Ceylan S
Growth Horm IGF Res; 2019 Apr; 45():1-5. PubMed ID: 30731342
[TBL] [Abstract][Full Text] [Related]
15. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.
Melmed S; Sternberg R; Cook D; Klibanski A; Chanson P; Bonert V; Vance ML; Rhew D; Kleinberg D; Barkan A
J Clin Endocrinol Metab; 2005 Jul; 90(7):4405-10. PubMed ID: 15827109
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide.
Broson-Chazot F; Houzard C; Ajzenberg C; Nocaudie M; Duet M; Mundler O; Marchandise X; Epelbaum J; Gomez De Alzaga M; Schäfer J; Meyerhof W; Sassolas G; Warnet A
Clin Endocrinol (Oxf); 1997 Nov; 47(5):589-98. PubMed ID: 9425399
[TBL] [Abstract][Full Text] [Related]
17. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: MANAGEMENT OF ACROMEGALY PATIENTS: WHAT IS THE ROLE OF PRE-OPERATIVE MEDICAL THERAPY?
Fleseriu M; Hoffman AR; Katznelson L;
Endocr Pract; 2015 Jun; 21(6):668-73. PubMed ID: 26135961
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
[TBL] [Abstract][Full Text] [Related]
19. Absence of somatostatin receptor type 2 A mutations and gip oncogene in pituitary somatotroph adenomas.
Petersenn S; Heyens M; Lüdecke DK; Beil FU; Schulte HM
Clin Endocrinol (Oxf); 2000 Jan; 52(1):35-42. PubMed ID: 10651751
[TBL] [Abstract][Full Text] [Related]
20. Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly.
Marques-Pamies M; Gil J; Valassi E; Hernández M; Biagetti B; Giménez-Palop O; Martínez S; Carrato C; Pons L; Villar-Taibo R; Araujo-Castro M; Blanco C; Simón I; Simó-Servat A; Xifra G; Vázquez F; Pavón I; García-Centeno R; Zavala R; Hanzu FA; Mora M; Aulinas A; Vilarrasa N; Librizzi S; Calatayud M; de Miguel P; Alvarez-Escola C; Picó A; Sampedro M; Salinas I; Fajardo-Montañana C; Cámara R; Bernabéu I; Jordà M; Webb SM; Marazuela M; Puig-Domingo M
Front Endocrinol (Lausanne); 2023; 14():1269787. PubMed ID: 38027102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
